The rise of drug-resistant organisms and the need to minimize side effects calls for a new approach to antibiotic therapy duration. This study explores tailoring the length of antibiotic treatment to patient recovery, focusing on whether adjusting therapy based on when the patient feels better is as effective as completing the prescribed course for acute respiratory tract infections (RTIs). The investigators will enroll 474 outpatients aged 18-75 with acute RTIs across 25 Spanish healthcare centers. Patients will be randomized into two groups: one following standard full-course antibiotic therapy, and another receiving a tailored approach, where treatment may be shortened based on clinical assessments. The primary outcome is clinical efficacy at day 14. Secondary outcomes include antibiotic duration, complications, and quality of life.
Background. Combating the rise of drug-resistant organisms and minimizing the side effects demand a shift in how we approach antibiotic therapy duration. A study focused on tailoring antibiotic length of therapy to patients\' needs as soon as they feel better, is a promising strategy. The investigators aim to assess whether adjusting the duration of antibiotic therapy according to individual patient needs, shortening it to the time when the patient feels better, proves as effective as completing the antibiotic course in acute respiratory tract infections (RTIs). Methods. The investigators plan to enroll a minimum of 474 outpatients ranging from 18 to 75 years of age with clinical features of acute RTIs across 25 Spanish primary healthcare centers. Patients diagnosed with acute lower RTIs or acute rhinosinusitis, deemed by clinicians to require a beta-lactam course, will be randomized to either usual care, involving a full-course antibiotic therapy based on current guidelines, or a tailored approach. In the intervention group, patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment and C-reactive protein rapid testing after completing two full days of antibiotic. Treatment will be discontinued if these clinical results are normal. The primary outcome will be overall clinical efficacy at day 14, while secondary outcomes include duration, doses of antibiotic taken, complications and reattendance within the first month, drug-related adverse events, antibiotic given, other therapies, days of severe and moderate symptoms, days of symptoms, absenteeism and health-related quality of life. All participants will be given a symptom diary, recording their symptoms each evening. Additionally, a cost-effectiveness study and qualitative studies involving clinicians and patients aimed at exploring the strategy\'s pros, cons, uptake, and satisfaction levels will be carried out. Discussion. The investigators will examine whether adults who present with symptoms of acute lower RTI or rhinosinusitis in general practice, who are treated with antibiotic courses until they feel better are as effective as longer standard courses. It is highly important that a possible reduction in the antibiotic course as soon as the patient feels better does not compromise patients' recovery or clinical course, which we will assess closely. This comprehensive approach aims to shed light on the practicality and impact of tailoring antibiotic duration in RTIs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
474
Patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment including vital signs (temperature, blood pressure, respiratory rate, pulse, and oxygen saturation) and C-reactive protein rapid testing after completing two full days of antibiotic.
The antibiotic course must be completed (7 days at least).
Clinical resolution
Number of patients with disappearance of fever, disappearance or improvement in overall condition (all scores \<2), such that no additional antimicrobial treatment is necessary.
Time frame: Day 14
Duration of antibiotic therapy
Number of patients discontinuing treatment in both groups and what day they discontinue recorded
Time frame: Day 14
Doses taken
Number of doses of antibiotic taken
Time frame: Day 14
Duration of severe symptoms
Number of days until the last day the patient scores 5 in any of the symptoms in the RTI diary symptom
Time frame: Day 14
Duration of moderate symptoms
Number of days until the last day the patient scores 3 in any of the symptoms in the RTI symptom diary.
Time frame: Day 14
Total resolution of symptoms
Number of days until the last day the patient scores 0 in any of the symptoms in the RTI symptom diary.
Time frame: Day 14
Re-attendance rate
Number of re-attendances to any doctor for new or worsening symptoms regarding the RTI regarding the infection
Time frame: Day 28
Complication rate
Number of complications related to the infection, such as visits to emergency departments and/or hospital admissions regarding the RTI
Time frame: Day 28
Absenteeism
Number of days of work absenteeism due to the infectious disease
Time frame: Day 14
Adverse events
Drug-associated adverse events related to the antibiotic and antibiotics changed
Time frame: Day 14
Use of other medication
Number of participants using antibiotics others than the study medication and other symptomatic therapies within the first two weeks
Time frame: Day 14
Health quality of life
Variation of the score of the health-related quality of life on days 14 and 28, compared to baseline, measured using the EuroQol instrument, including visual analogical scale, ranging from 0 (worst health condition) to 100 (best health condition)
Time frame: Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.